Frits Van Rhee
Concepts (569)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Myeloma | 152 | 2024 | 3035 | 11.040 |
Why?
| Antibodies, Monoclonal | 26 | 2024 | 562 | 6.310 |
Why?
| Antineoplastic Agents | 18 | 2024 | 1300 | 3.370 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 41 | 2024 | 1056 | 3.290 |
Why?
| Hematopoietic Stem Cell Transplantation | 26 | 2024 | 573 | 2.900 |
Why?
| Humans | 200 | 2024 | 54284 | 2.080 |
Why?
| Monoclonal Gammopathy of Undetermined Significance | 9 | 2023 | 108 | 1.960 |
Why?
| Neoplasm Recurrence, Local | 15 | 2024 | 644 | 1.930 |
Why?
| Thalidomide | 23 | 2019 | 397 | 1.930 |
Why?
| Killer Cells, Natural | 7 | 2020 | 107 | 1.810 |
Why?
| Immunotherapy, Adoptive | 8 | 2024 | 134 | 1.770 |
Why?
| Interleukin-6 | 12 | 2023 | 315 | 1.750 |
Why?
| Hematologic Neoplasms | 3 | 2022 | 99 | 1.690 |
Why?
| Neoplasm Proteins | 13 | 2022 | 359 | 1.660 |
Why?
| Antigens, Neoplasm | 6 | 2014 | 170 | 1.530 |
Why?
| Clinical Trials as Topic | 13 | 2022 | 490 | 1.490 |
Why?
| Stem Cell Transplantation | 10 | 2022 | 196 | 1.440 |
Why?
| Middle Aged | 67 | 2022 | 13088 | 1.350 |
Why?
| Prognosis | 44 | 2024 | 2118 | 1.320 |
Why?
| Gene Expression Regulation, Neoplastic | 20 | 2022 | 866 | 1.320 |
Why?
| Combined Modality Therapy | 19 | 2024 | 692 | 1.320 |
Why?
| Chromosomes, Human, Pair 1 | 9 | 2023 | 113 | 1.310 |
Why?
| Herpesvirus 8, Human | 7 | 2021 | 90 | 1.300 |
Why?
| Translocation, Genetic | 10 | 2022 | 287 | 1.240 |
Why?
| Boronic Acids | 12 | 2013 | 197 | 1.180 |
Why?
| Pyrazines | 12 | 2013 | 203 | 1.180 |
Why?
| Treatment Outcome | 46 | 2022 | 5604 | 1.130 |
Why?
| Aged | 67 | 2021 | 10054 | 1.130 |
Why?
| Bone Marrow | 18 | 2024 | 411 | 1.100 |
Why?
| Immunotherapy | 6 | 2024 | 263 | 1.040 |
Why?
| Gene Expression Profiling | 26 | 2023 | 1138 | 1.010 |
Why?
| Disease-Free Survival | 24 | 2019 | 485 | 0.990 |
Why?
| Female | 78 | 2021 | 28441 | 0.990 |
Why?
| Adult | 47 | 2022 | 14207 | 0.980 |
Why?
| Male | 75 | 2022 | 27334 | 0.970 |
Why?
| Transplantation, Autologous | 24 | 2024 | 476 | 0.970 |
Why?
| T-Lymphocytes, Cytotoxic | 4 | 2014 | 72 | 0.940 |
Why?
| Melphalan | 9 | 2020 | 180 | 0.940 |
Why?
| B-Lymphocytes | 4 | 2022 | 176 | 0.920 |
Why?
| Cancer Vaccines | 3 | 2010 | 103 | 0.900 |
Why?
| Follow-Up Studies | 26 | 2024 | 2387 | 0.890 |
Why?
| Hyperhidrosis | 1 | 2022 | 3 | 0.890 |
Why?
| Plasma Cells | 11 | 2023 | 238 | 0.890 |
Why?
| Sweat | 1 | 2022 | 7 | 0.880 |
Why?
| Proteasome Inhibitors | 4 | 2018 | 110 | 0.880 |
Why?
| Antibodies, Bispecific | 4 | 2024 | 43 | 0.870 |
Why?
| Survival Rate | 24 | 2020 | 951 | 0.850 |
Why?
| Lymphoma, B-Cell | 3 | 2022 | 62 | 0.840 |
Why?
| Drug Approval | 1 | 2022 | 47 | 0.840 |
Why?
| Ehrlichia chaffeensis | 1 | 2021 | 8 | 0.800 |
Why?
| Patient Participation | 1 | 2022 | 70 | 0.800 |
Why?
| Cryosurgery | 1 | 2021 | 38 | 0.790 |
Why?
| Ehrlichiosis | 1 | 2021 | 20 | 0.790 |
Why?
| Immunoglobulin Light Chains | 3 | 2017 | 101 | 0.770 |
Why?
| T-Lymphocytes | 8 | 2024 | 373 | 0.770 |
Why?
| Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 29 | 0.770 |
Why?
| Dexamethasone | 13 | 2024 | 435 | 0.760 |
Why?
| B-Cell Maturation Antigen | 6 | 2024 | 72 | 0.760 |
Why?
| Embolization, Therapeutic | 1 | 2021 | 98 | 0.740 |
Why?
| Cell Proliferation | 10 | 2023 | 1096 | 0.710 |
Why?
| Disease Progression | 16 | 2023 | 913 | 0.710 |
Why?
| Chromosomal Instability | 1 | 2019 | 17 | 0.710 |
Why?
| Neoplasms, Plasma Cell | 3 | 2024 | 39 | 0.690 |
Why?
| Adrenal Cortex Hormones | 2 | 2023 | 95 | 0.680 |
Why?
| Membrane Proteins | 3 | 2006 | 389 | 0.670 |
Why?
| Immunologic Factors | 2 | 2018 | 130 | 0.660 |
Why?
| Neoplasm, Residual | 8 | 2022 | 166 | 0.650 |
Why?
| Epigenesis, Genetic | 4 | 2023 | 399 | 0.650 |
Why?
| POEMS Syndrome | 1 | 2018 | 32 | 0.630 |
Why?
| Chromosome Aberrations | 12 | 2023 | 316 | 0.630 |
Why?
| Dendritic Cells | 3 | 2014 | 142 | 0.630 |
Why?
| Atrial Fibrillation | 2 | 2022 | 197 | 0.620 |
Why?
| Survival Analysis | 17 | 2023 | 735 | 0.620 |
Why?
| Prealbumin | 2 | 2014 | 24 | 0.610 |
Why?
| Thyroid Neoplasms | 1 | 2019 | 162 | 0.590 |
Why?
| Receptors, Interleukin-6 | 2 | 2014 | 29 | 0.580 |
Why?
| Antibodies, Monoclonal, Humanized | 6 | 2023 | 240 | 0.580 |
Why?
| Positron-Emission Tomography | 7 | 2022 | 322 | 0.570 |
Why?
| Cardiomyopathies | 2 | 2014 | 129 | 0.540 |
Why?
| Osteolysis | 4 | 2022 | 88 | 0.510 |
Why?
| Mutation | 10 | 2022 | 1501 | 0.500 |
Why?
| Immunotoxins | 1 | 2014 | 5 | 0.500 |
Why?
| Cytotoxicity, Immunologic | 2 | 2012 | 62 | 0.490 |
Why?
| Clonal Evolution | 3 | 2020 | 60 | 0.480 |
Why?
| Practice Guidelines as Topic | 4 | 2023 | 492 | 0.460 |
Why?
| Cyclophosphamide | 5 | 2021 | 172 | 0.460 |
Why?
| Transplantation, Homologous | 5 | 2017 | 155 | 0.460 |
Why?
| Amyloidosis | 1 | 2014 | 85 | 0.450 |
Why?
| Tumor Microenvironment | 5 | 2023 | 209 | 0.440 |
Why?
| Aged, 80 and over | 17 | 2021 | 3431 | 0.440 |
Why?
| Health Status | 1 | 2015 | 368 | 0.440 |
Why?
| Fluorodeoxyglucose F18 | 6 | 2021 | 205 | 0.430 |
Why?
| Remission Induction | 13 | 2021 | 221 | 0.430 |
Why?
| Neutropenia | 2 | 2023 | 120 | 0.420 |
Why?
| Receptors, KIR | 2 | 2008 | 15 | 0.420 |
Why?
| Risk Factors | 18 | 2021 | 3935 | 0.410 |
Why?
| Polymorphism, Single Nucleotide | 2 | 2020 | 552 | 0.400 |
Why?
| Pyrimidines | 2 | 2022 | 196 | 0.400 |
Why?
| Bone Diseases | 3 | 2021 | 109 | 0.390 |
Why?
| Azacitidine | 1 | 2010 | 37 | 0.390 |
Why?
| Thrombocytopenia | 2 | 2022 | 99 | 0.390 |
Why?
| Dose-Response Relationship, Drug | 8 | 2020 | 1476 | 0.390 |
Why?
| Benzamides | 1 | 2010 | 54 | 0.390 |
Why?
| Evolution, Molecular | 2 | 2021 | 103 | 0.380 |
Why?
| Recurrence | 11 | 2021 | 690 | 0.380 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2010 | 56 | 0.380 |
Why?
| C-Reactive Protein | 6 | 2022 | 159 | 0.370 |
Why?
| Prednisone | 2 | 2021 | 111 | 0.370 |
Why?
| Doxorubicin | 6 | 2021 | 259 | 0.360 |
Why?
| TOR Serine-Threonine Kinases | 2 | 2020 | 85 | 0.350 |
Why?
| Drug Administration Schedule | 5 | 2015 | 401 | 0.350 |
Why?
| Chromosome Deletion | 5 | 2023 | 150 | 0.350 |
Why?
| Metaphase | 4 | 2016 | 55 | 0.340 |
Why?
| Vaccination | 4 | 2022 | 294 | 0.340 |
Why?
| Pelvis | 2 | 2021 | 76 | 0.340 |
Why?
| Membrane Glycoproteins | 2 | 2009 | 269 | 0.330 |
Why?
| Quality of Life | 1 | 2015 | 922 | 0.330 |
Why?
| Paraproteinemias | 3 | 2022 | 80 | 0.330 |
Why?
| Proportional Hazards Models | 7 | 2024 | 431 | 0.320 |
Why?
| Placebo Effect | 2 | 2020 | 19 | 0.320 |
Why?
| Bone Neoplasms | 4 | 2013 | 193 | 0.320 |
Why?
| Adoptive Transfer | 1 | 2007 | 38 | 0.310 |
Why?
| Histocompatibility Antigens Class I | 1 | 2007 | 52 | 0.310 |
Why?
| Chromatin | 3 | 2023 | 156 | 0.310 |
Why?
| Cytogenetic Analysis | 5 | 2023 | 90 | 0.300 |
Why?
| DNA Methylation | 4 | 2023 | 574 | 0.300 |
Why?
| Animals | 14 | 2024 | 14385 | 0.290 |
Why?
| Drug Resistance, Neoplasm | 6 | 2021 | 309 | 0.290 |
Why?
| Vincristine | 3 | 2021 | 98 | 0.290 |
Why?
| Mice, SCID | 6 | 2013 | 196 | 0.290 |
Why?
| Risk Assessment | 9 | 2022 | 1361 | 0.280 |
Why?
| Cell Membrane | 1 | 2007 | 278 | 0.280 |
Why?
| In Situ Hybridization, Fluorescence | 5 | 2023 | 278 | 0.280 |
Why?
| Down-Regulation | 1 | 2007 | 388 | 0.280 |
Why?
| Angiogenesis Inhibitors | 5 | 2010 | 203 | 0.280 |
Why?
| Neoplasm Staging | 6 | 2024 | 806 | 0.270 |
Why?
| Chromosomes, Human, Pair 17 | 2 | 2017 | 43 | 0.270 |
Why?
| Transplantation Conditioning | 5 | 2008 | 86 | 0.270 |
Why?
| Disease Management | 2 | 2018 | 184 | 0.270 |
Why?
| Cell Line, Tumor | 9 | 2023 | 1550 | 0.260 |
Why?
| Infusions, Intravenous | 3 | 2015 | 231 | 0.260 |
Why?
| Bone Resorption | 2 | 2022 | 326 | 0.260 |
Why?
| Antibody Formation | 1 | 2005 | 69 | 0.260 |
Why?
| Fever | 2 | 2022 | 129 | 0.250 |
Why?
| Polycomb Repressive Complex 2 | 2 | 2021 | 50 | 0.250 |
Why?
| CD8-Positive T-Lymphocytes | 2 | 2020 | 116 | 0.250 |
Why?
| Pentaerythritol Tetranitrate | 1 | 2024 | 6 | 0.250 |
Why?
| Monocytes | 2 | 2020 | 156 | 0.240 |
Why?
| Flow Cytometry | 4 | 2012 | 546 | 0.240 |
Why?
| Time Factors | 11 | 2021 | 3213 | 0.230 |
Why?
| Gene Expression | 2 | 2018 | 664 | 0.230 |
Why?
| High-Throughput Nucleotide Sequencing | 3 | 2022 | 206 | 0.230 |
Why?
| Epstein-Barr Virus Infections | 2 | 2020 | 34 | 0.230 |
Why?
| Proteasome Endopeptidase Complex | 3 | 2011 | 131 | 0.230 |
Why?
| Cell Cycle Proteins | 2 | 2022 | 199 | 0.230 |
Why?
| Chromans | 1 | 2024 | 62 | 0.230 |
Why?
| Integrin beta Chains | 1 | 2023 | 14 | 0.230 |
Why?
| Blotting, Western | 3 | 2015 | 683 | 0.230 |
Why?
| Mice | 10 | 2024 | 6413 | 0.230 |
Why?
| Integrins | 1 | 2023 | 36 | 0.230 |
Why?
| Signal Transduction | 6 | 2021 | 1753 | 0.220 |
Why?
| Prospective Studies | 8 | 2022 | 2604 | 0.220 |
Why?
| Double-Blind Method | 2 | 2015 | 742 | 0.220 |
Why?
| Sweating | 1 | 2022 | 19 | 0.220 |
Why?
| Cross-Sectional Studies | 3 | 2023 | 1693 | 0.220 |
Why?
| Young Adult | 5 | 2020 | 4318 | 0.220 |
Why?
| Consensus | 2 | 2020 | 157 | 0.210 |
Why?
| Radiation-Protective Agents | 1 | 2024 | 116 | 0.210 |
Why?
| Case-Control Studies | 5 | 2019 | 1228 | 0.210 |
Why?
| DNA, Intergenic | 1 | 2022 | 6 | 0.210 |
Why?
| Proto-Oncogene Proteins B-raf | 2 | 2020 | 90 | 0.210 |
Why?
| Immunoconjugates | 1 | 2022 | 38 | 0.210 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2022 | 50 | 0.210 |
Why?
| Tumor Cells, Cultured | 4 | 2013 | 477 | 0.210 |
Why?
| Kaplan-Meier Estimate | 10 | 2016 | 514 | 0.210 |
Why?
| Tumor Suppressor Protein p53 | 2 | 2017 | 250 | 0.210 |
Why?
| Waldenstrom Macroglobulinemia | 1 | 2022 | 41 | 0.210 |
Why?
| United States Food and Drug Administration | 1 | 2022 | 97 | 0.210 |
Why?
| Proteomics | 3 | 2021 | 343 | 0.210 |
Why?
| Epigenomics | 1 | 2021 | 67 | 0.200 |
Why?
| Mediastinum | 1 | 2021 | 27 | 0.200 |
Why?
| Chromosomes, Human, Pair 14 | 3 | 2020 | 76 | 0.200 |
Why?
| Receptors, Glucocorticoid | 2 | 2012 | 36 | 0.200 |
Why?
| United States | 4 | 2022 | 5217 | 0.200 |
Why?
| Registries | 2 | 2022 | 553 | 0.200 |
Why?
| Ubiquitination | 1 | 2021 | 47 | 0.200 |
Why?
| Influenza, Human | 1 | 2022 | 120 | 0.200 |
Why?
| Phosphatidylinositol 3-Kinases | 2 | 2019 | 153 | 0.200 |
Why?
| Axilla | 1 | 2021 | 101 | 0.200 |
Why?
| Genetic Predisposition to Disease | 2 | 2022 | 570 | 0.200 |
Why?
| Multiple Organ Failure | 1 | 2021 | 56 | 0.200 |
Why?
| Alleles | 3 | 2021 | 277 | 0.200 |
Why?
| Salvage Therapy | 6 | 2013 | 145 | 0.190 |
Why?
| Proto-Oncogene Proteins c-maf | 2 | 2020 | 20 | 0.190 |
Why?
| Epstein-Barr Virus Nuclear Antigens | 1 | 2020 | 1 | 0.190 |
Why?
| Diffusion Magnetic Resonance Imaging | 2 | 2019 | 126 | 0.190 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 106 | 0.190 |
Why?
| Rare Diseases | 1 | 2020 | 46 | 0.190 |
Why?
| Genome-Wide Association Study | 2 | 2020 | 190 | 0.190 |
Why?
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 105 | 0.190 |
Why?
| Interferon-gamma | 3 | 2014 | 195 | 0.190 |
Why?
| Apoptosis | 5 | 2018 | 1300 | 0.190 |
Why?
| Genes, Tumor Suppressor | 2 | 2021 | 85 | 0.190 |
Why?
| Exosome Multienzyme Ribonuclease Complex | 1 | 2020 | 14 | 0.180 |
Why?
| Leukemia, Plasma Cell | 1 | 2020 | 34 | 0.180 |
Why?
| Myelodysplastic Syndromes | 2 | 2013 | 79 | 0.180 |
Why?
| Interferon Type I | 1 | 2020 | 30 | 0.180 |
Why?
| Radiopharmaceuticals | 4 | 2021 | 238 | 0.180 |
Why?
| Cytokines | 2 | 2014 | 676 | 0.180 |
Why?
| Cell Cycle | 1 | 2021 | 275 | 0.180 |
Why?
| Research Design | 2 | 2020 | 374 | 0.180 |
Why?
| Gene Amplification | 1 | 2019 | 57 | 0.180 |
Why?
| Measles virus | 1 | 2019 | 9 | 0.180 |
Why?
| Multivariate Analysis | 8 | 2021 | 643 | 0.180 |
Why?
| Hematopoiesis, Extramedullary | 1 | 2019 | 10 | 0.180 |
Why?
| Measles | 1 | 2019 | 9 | 0.180 |
Why?
| Genomics | 4 | 2023 | 310 | 0.180 |
Why?
| Gene Regulatory Networks | 1 | 2020 | 124 | 0.180 |
Why?
| Oncolytic Virotherapy | 1 | 2019 | 18 | 0.180 |
Why?
| Health Status Disparities | 1 | 2022 | 219 | 0.170 |
Why?
| Data Collection | 1 | 2020 | 321 | 0.170 |
Why?
| Immunohistochemistry | 2 | 2015 | 1089 | 0.170 |
Why?
| DNA | 1 | 2023 | 581 | 0.170 |
Why?
| Sirolimus | 1 | 2019 | 65 | 0.170 |
Why?
| Patient Safety | 1 | 2020 | 121 | 0.170 |
Why?
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2018 | 11 | 0.170 |
Why?
| Healthcare Disparities | 1 | 2022 | 271 | 0.170 |
Why?
| Biopsy | 5 | 2018 | 692 | 0.170 |
Why?
| Syndrome | 1 | 2019 | 252 | 0.170 |
Why?
| Precancerous Conditions | 2 | 2010 | 93 | 0.170 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 176 | 0.170 |
Why?
| Graft vs Host Disease | 4 | 2007 | 83 | 0.170 |
Why?
| Evidence-Based Medicine | 2 | 2018 | 281 | 0.170 |
Why?
| MafB Transcription Factor | 1 | 2018 | 11 | 0.170 |
Why?
| Cell Differentiation | 6 | 2022 | 720 | 0.170 |
Why?
| Spleen | 1 | 2019 | 186 | 0.160 |
Why?
| Genomic Instability | 2 | 2016 | 95 | 0.160 |
Why?
| Phosphotransferases | 1 | 2018 | 24 | 0.160 |
Why?
| Immunomodulation | 1 | 2018 | 42 | 0.160 |
Why?
| Plasma | 1 | 2018 | 52 | 0.160 |
Why?
| Myeloablative Agonists | 2 | 2008 | 33 | 0.160 |
Why?
| Chemokines | 1 | 2018 | 96 | 0.160 |
Why?
| Hematopoietic Stem Cell Mobilization | 2 | 2008 | 61 | 0.160 |
Why?
| Genes, Neoplasm | 2 | 2015 | 36 | 0.160 |
Why?
| Adipocytes | 1 | 2018 | 129 | 0.160 |
Why?
| Osteoclasts | 3 | 2022 | 469 | 0.150 |
Why?
| Gene Dosage | 2 | 2015 | 91 | 0.150 |
Why?
| Gene Rearrangement | 1 | 2018 | 76 | 0.150 |
Why?
| Magnetic Resonance Imaging | 5 | 2013 | 1604 | 0.150 |
Why?
| Hexokinase | 1 | 2017 | 18 | 0.150 |
Why?
| Heterozygote | 2 | 2014 | 96 | 0.150 |
Why?
| Communication | 1 | 2019 | 273 | 0.150 |
Why?
| HLA-A Antigens | 2 | 2007 | 13 | 0.150 |
Why?
| Calcification, Physiologic | 1 | 2017 | 42 | 0.150 |
Why?
| Models, Biological | 2 | 2018 | 823 | 0.150 |
Why?
| Protein-Tyrosine Kinases | 2 | 2018 | 101 | 0.150 |
Why?
| Drug Therapy, Combination | 1 | 2018 | 426 | 0.140 |
Why?
| Gene Frequency | 2 | 2013 | 120 | 0.140 |
Why?
| Oligonucleotide Array Sequence Analysis | 5 | 2010 | 474 | 0.140 |
Why?
| Syndecan-1 | 4 | 2021 | 82 | 0.140 |
Why?
| Transcriptome | 4 | 2020 | 346 | 0.140 |
Why?
| Confidence Intervals | 2 | 2014 | 167 | 0.140 |
Why?
| Lymphocyte Activation | 2 | 2017 | 197 | 0.140 |
Why?
| Tumor Burden | 3 | 2020 | 142 | 0.140 |
Why?
| Immunity, Innate | 1 | 2016 | 114 | 0.140 |
Why?
| Erythrocyte Indices | 1 | 2015 | 8 | 0.140 |
Why?
| Biomarkers, Pharmacological | 2 | 2012 | 28 | 0.140 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2017 | 206 | 0.130 |
Why?
| DNA Copy Number Variations | 3 | 2022 | 114 | 0.130 |
Why?
| Adolescent | 5 | 2020 | 6897 | 0.130 |
Why?
| Critical Illness | 1 | 2018 | 344 | 0.130 |
Why?
| Coculture Techniques | 2 | 2013 | 160 | 0.130 |
Why?
| Hemoglobins | 2 | 2013 | 126 | 0.130 |
Why?
| Cysteine-Rich Protein 61 | 1 | 2014 | 4 | 0.130 |
Why?
| Hematologic Diseases | 1 | 2014 | 25 | 0.120 |
Why?
| Half-Life | 1 | 2014 | 92 | 0.120 |
Why?
| International Cooperation | 1 | 2014 | 63 | 0.120 |
Why?
| Fatigue | 1 | 2015 | 129 | 0.120 |
Why?
| Area Under Curve | 1 | 2014 | 205 | 0.120 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 314 | 0.120 |
Why?
| Amyloid Neuropathies, Familial | 1 | 2013 | 5 | 0.120 |
Why?
| Iron | 1 | 2015 | 158 | 0.120 |
Why?
| ROC Curve | 1 | 2014 | 259 | 0.120 |
Why?
| Antineoplastic Agents, Alkylating | 3 | 2008 | 74 | 0.120 |
Why?
| Antibodies | 2 | 2024 | 178 | 0.120 |
Why?
| Reference Values | 1 | 2014 | 354 | 0.120 |
Why?
| Emotions | 1 | 2015 | 168 | 0.120 |
Why?
| Administration, Metronomic | 1 | 2013 | 7 | 0.120 |
Why?
| Neoplasms, Glandular and Epithelial | 1 | 2014 | 48 | 0.120 |
Why?
| Cystatin M | 2 | 2024 | 21 | 0.120 |
Why?
| Renal Insufficiency | 2 | 2021 | 138 | 0.120 |
Why?
| Nicotinamide Phosphoribosyltransferase | 1 | 2013 | 6 | 0.110 |
Why?
| Central Nervous System Neoplasms | 1 | 2013 | 57 | 0.110 |
Why?
| Severity of Illness Index | 2 | 2014 | 1084 | 0.110 |
Why?
| Inflammation Mediators | 1 | 2014 | 128 | 0.110 |
Why?
| Retrospective Studies | 7 | 2024 | 6432 | 0.110 |
Why?
| beta Catenin | 1 | 2013 | 102 | 0.110 |
Why?
| Disease Models, Animal | 2 | 2016 | 1639 | 0.110 |
Why?
| Oligopeptides | 1 | 2013 | 95 | 0.110 |
Why?
| Antibody-Dependent Cell Cytotoxicity | 2 | 2009 | 15 | 0.110 |
Why?
| Cisplatin | 4 | 2013 | 352 | 0.110 |
Why?
| Myelolipoma | 1 | 2012 | 10 | 0.110 |
Why?
| Leukemia | 1 | 2013 | 69 | 0.110 |
Why?
| Lymph Nodes | 3 | 2021 | 284 | 0.110 |
Why?
| Venous Thrombosis | 2 | 2004 | 102 | 0.110 |
Why?
| Mental Health | 1 | 2015 | 245 | 0.110 |
Why?
| Interleukin Receptor Common gamma Subunit | 1 | 2012 | 10 | 0.110 |
Why?
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2012 | 11 | 0.110 |
Why?
| Maintenance Chemotherapy | 1 | 2012 | 48 | 0.110 |
Why?
| Clone Cells | 2 | 2023 | 89 | 0.110 |
Why?
| Cell Survival | 2 | 2020 | 657 | 0.110 |
Why?
| Interleukin-2 | 1 | 2012 | 75 | 0.110 |
Why?
| Mice, Inbred NOD | 1 | 2012 | 99 | 0.100 |
Why?
| Cell Movement | 1 | 2013 | 271 | 0.100 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2013 | 230 | 0.100 |
Why?
| Immunoenzyme Techniques | 1 | 2012 | 165 | 0.100 |
Why?
| Hemangioma | 1 | 2013 | 83 | 0.100 |
Why?
| Pain | 1 | 2015 | 405 | 0.100 |
Why?
| Models, Genetic | 2 | 2016 | 209 | 0.100 |
Why?
| Neoplasms, Second Primary | 1 | 2012 | 77 | 0.100 |
Why?
| Soft Tissue Neoplasms | 1 | 2012 | 65 | 0.100 |
Why?
| Genotype | 1 | 2013 | 599 | 0.100 |
Why?
| Arkansas | 5 | 2021 | 2100 | 0.100 |
Why?
| Transduction, Genetic | 2 | 2014 | 50 | 0.100 |
Why?
| Chemokine CXCL13 | 2 | 2022 | 4 | 0.100 |
Why?
| Transcriptional Elongation Factors | 2 | 2022 | 28 | 0.100 |
Why?
| Peripheral Blood Stem Cell Transplantation | 2 | 2008 | 57 | 0.100 |
Why?
| Mutation Rate | 2 | 2021 | 40 | 0.100 |
Why?
| CD40 Ligand | 1 | 2010 | 15 | 0.100 |
Why?
| Immunoglobulin Idiotypes | 1 | 2010 | 18 | 0.100 |
Why?
| Hypersensitivity, Delayed | 1 | 2010 | 21 | 0.100 |
Why?
| Models, Statistical | 2 | 2014 | 259 | 0.090 |
Why?
| Interleukin-4 | 1 | 2010 | 48 | 0.090 |
Why?
| Secondary Prevention | 1 | 2010 | 89 | 0.090 |
Why?
| HIV Seropositivity | 1 | 2010 | 28 | 0.090 |
Why?
| Eukaryotic Initiation Factor-2 | 1 | 2010 | 18 | 0.090 |
Why?
| Immunity, Cellular | 1 | 2010 | 80 | 0.090 |
Why?
| Adjuvants, Immunologic | 1 | 2010 | 61 | 0.090 |
Why?
| Up-Regulation | 4 | 2018 | 508 | 0.090 |
Why?
| Etoposide | 2 | 2007 | 85 | 0.090 |
Why?
| Transplantation, Heterologous | 1 | 2009 | 77 | 0.090 |
Why?
| Cell Line | 2 | 2013 | 1153 | 0.090 |
Why?
| Cells, Cultured | 3 | 2013 | 1737 | 0.090 |
Why?
| Placenta | 1 | 2011 | 135 | 0.090 |
Why?
| Ovarian Neoplasms | 1 | 2014 | 472 | 0.090 |
Why?
| Longitudinal Studies | 3 | 2020 | 746 | 0.080 |
Why?
| Cytotoxicity Tests, Immunologic | 1 | 2008 | 31 | 0.080 |
Why?
| Radiography | 4 | 2012 | 524 | 0.080 |
Why?
| Histones | 2 | 2021 | 335 | 0.080 |
Why?
| Polymerase Chain Reaction | 1 | 2010 | 531 | 0.080 |
Why?
| Lymphocyte Subsets | 1 | 2008 | 13 | 0.080 |
Why?
| Immunoglobulin lambda-Chains | 1 | 2008 | 18 | 0.080 |
Why?
| Granulocyte Colony-Stimulating Factor | 1 | 2008 | 69 | 0.080 |
Why?
| Cytogenetics | 1 | 2008 | 28 | 0.080 |
Why?
| Bone and Bones | 3 | 2021 | 516 | 0.080 |
Why?
| Haplotypes | 1 | 2008 | 105 | 0.080 |
Why?
| Receptors, Immunologic | 1 | 2008 | 37 | 0.080 |
Why?
| Transcription Factors | 2 | 2023 | 622 | 0.080 |
Why?
| Liver Neoplasms | 1 | 2012 | 352 | 0.080 |
Why?
| Gene Deletion | 1 | 2009 | 293 | 0.080 |
Why?
| Neoplastic Stem Cells | 1 | 2009 | 103 | 0.080 |
Why?
| Ligands | 1 | 2008 | 230 | 0.080 |
Why?
| Twins | 1 | 2007 | 32 | 0.080 |
Why?
| Osteogenesis | 1 | 2011 | 377 | 0.080 |
Why?
| Busulfan | 1 | 2007 | 18 | 0.080 |
Why?
| Herpesviridae Infections | 2 | 2019 | 46 | 0.080 |
Why?
| Immunophenotyping | 1 | 2007 | 117 | 0.080 |
Why?
| Diphosphonates | 1 | 2008 | 96 | 0.080 |
Why?
| Leukocytes, Mononuclear | 1 | 2007 | 133 | 0.070 |
Why?
| Antimetabolites | 1 | 2006 | 12 | 0.070 |
Why?
| Caspases | 2 | 2018 | 146 | 0.070 |
Why?
| Creatinine | 1 | 2007 | 169 | 0.070 |
Why?
| Blood Proteins | 1 | 2007 | 100 | 0.070 |
Why?
| Antibodies, Neoplasm | 1 | 2006 | 35 | 0.070 |
Why?
| Graft vs Leukemia Effect | 1 | 2006 | 2 | 0.070 |
Why?
| Chromosome Banding | 1 | 2006 | 28 | 0.070 |
Why?
| Immunosuppressive Agents | 1 | 2008 | 248 | 0.070 |
Why?
| Plasmacytoma | 1 | 2006 | 47 | 0.070 |
Why?
| Skin Neoplasms | 1 | 2012 | 532 | 0.070 |
Why?
| HLA-A2 Antigen | 1 | 2005 | 12 | 0.070 |
Why?
| Amiloride | 1 | 2005 | 14 | 0.070 |
Why?
| Cohort Studies | 3 | 2020 | 1543 | 0.070 |
Why?
| MicroRNAs | 1 | 2010 | 386 | 0.070 |
Why?
| Bone Marrow Transplantation | 2 | 2022 | 149 | 0.070 |
Why?
| Imaging, Three-Dimensional | 2 | 2017 | 171 | 0.070 |
Why?
| Poly(ADP-ribose) Polymerases | 2 | 2016 | 43 | 0.060 |
Why?
| Sensitivity and Specificity | 1 | 2007 | 923 | 0.060 |
Why?
| Predictive Value of Tests | 3 | 2018 | 1048 | 0.060 |
Why?
| Enoxaparin | 1 | 2004 | 25 | 0.060 |
Why?
| Ferritins | 1 | 2024 | 31 | 0.060 |
Why?
| Myeloid Progenitor Cells | 1 | 2023 | 19 | 0.060 |
Why?
| X-Ray Microtomography | 1 | 2024 | 82 | 0.060 |
Why?
| NF-kappa B | 2 | 2018 | 335 | 0.060 |
Why?
| Macaca mulatta | 1 | 2024 | 106 | 0.060 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2024 | 55 | 0.060 |
Why?
| Epidemiologic Methods | 3 | 2008 | 49 | 0.060 |
Why?
| Gene Silencing | 2 | 2016 | 129 | 0.060 |
Why?
| DNA, Neoplasm | 2 | 2020 | 171 | 0.060 |
Why?
| Fibroblasts | 1 | 2005 | 386 | 0.060 |
Why?
| Neoplasms | 1 | 2014 | 1316 | 0.060 |
Why?
| Cell Communication | 1 | 2023 | 72 | 0.060 |
Why?
| Cluster Analysis | 3 | 2010 | 249 | 0.060 |
Why?
| TNF Receptor-Associated Factor 3 | 1 | 2022 | 14 | 0.060 |
Why?
| Vitamin E | 1 | 2024 | 107 | 0.050 |
Why?
| Patients | 1 | 2022 | 53 | 0.050 |
Why?
| Geography | 1 | 2022 | 81 | 0.050 |
Why?
| Guanine Nucleotide Exchange Factors | 1 | 2022 | 17 | 0.050 |
Why?
| Myeloid Differentiation Factor 88 | 1 | 2022 | 40 | 0.050 |
Why?
| Inheritance Patterns | 1 | 2022 | 27 | 0.050 |
Why?
| Quantitative Trait Loci | 1 | 2022 | 51 | 0.050 |
Why?
| Primary Cell Culture | 1 | 2022 | 65 | 0.050 |
Why?
| Oncogenes | 1 | 2021 | 63 | 0.050 |
Why?
| Chromosomal Proteins, Non-Histone | 1 | 2022 | 44 | 0.050 |
Why?
| Risk | 2 | 2014 | 343 | 0.050 |
Why?
| Patient Selection | 1 | 2023 | 286 | 0.050 |
Why?
| Age of Onset | 2 | 2013 | 117 | 0.050 |
Why?
| Anticoagulants | 1 | 2004 | 270 | 0.050 |
Why?
| Phylogeny | 1 | 2022 | 269 | 0.050 |
Why?
| RANK Ligand | 1 | 2022 | 183 | 0.050 |
Why?
| Boron Compounds | 1 | 2021 | 18 | 0.050 |
Why?
| SOXC Transcription Factors | 1 | 2021 | 14 | 0.050 |
Why?
| Child, Preschool | 2 | 2020 | 4147 | 0.050 |
Why?
| Polymorphism, Genetic | 1 | 2022 | 193 | 0.050 |
Why?
| Transcriptional Activation | 1 | 2021 | 134 | 0.050 |
Why?
| Rabbits | 2 | 2013 | 425 | 0.050 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2022 | 208 | 0.050 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 69 | 0.050 |
Why?
| Glycine | 1 | 2021 | 70 | 0.050 |
Why?
| Cyclin D2 | 1 | 2020 | 20 | 0.050 |
Why?
| Spatio-Temporal Analysis | 1 | 2020 | 10 | 0.050 |
Why?
| Aneuploidy | 1 | 2020 | 23 | 0.050 |
Why?
| Edema | 1 | 2021 | 74 | 0.050 |
Why?
| Fibrosis | 1 | 2021 | 208 | 0.050 |
Why?
| Chromosomes, Human, Pair 4 | 1 | 2020 | 30 | 0.050 |
Why?
| Gene Expression Regulation, Leukemic | 1 | 2020 | 36 | 0.050 |
Why?
| Histone Code | 1 | 2020 | 32 | 0.050 |
Why?
| Cyclin D1 | 1 | 2020 | 60 | 0.050 |
Why?
| Chromosomes, Human, Pair 11 | 1 | 2020 | 54 | 0.050 |
Why?
| Base Sequence | 1 | 2022 | 719 | 0.050 |
Why?
| ras Proteins | 1 | 2020 | 70 | 0.050 |
Why?
| Repressor Proteins | 1 | 2022 | 165 | 0.050 |
Why?
| Protein Kinase Inhibitors | 1 | 2022 | 216 | 0.050 |
Why?
| Genome, Human | 1 | 2021 | 131 | 0.050 |
Why?
| Single-Cell Analysis | 1 | 2020 | 56 | 0.050 |
Why?
| Genetic Loci | 1 | 2020 | 58 | 0.040 |
Why?
| False Negative Reactions | 1 | 2019 | 36 | 0.040 |
Why?
| Herpesvirus 4, Human | 1 | 2019 | 38 | 0.040 |
Why?
| Neoplasm Invasiveness | 1 | 2020 | 295 | 0.040 |
Why?
| Mice, Transgenic | 1 | 2021 | 656 | 0.040 |
Why?
| DNA Mutational Analysis | 1 | 2020 | 217 | 0.040 |
Why?
| Europe | 1 | 2019 | 102 | 0.040 |
Why?
| Incidence | 2 | 2013 | 1082 | 0.040 |
Why?
| Genetic Variation | 1 | 2020 | 253 | 0.040 |
Why?
| Communicable Disease Control | 1 | 2019 | 39 | 0.040 |
Why?
| beta 2-Microglobulin | 2 | 2009 | 35 | 0.040 |
Why?
| Virus Diseases | 1 | 2019 | 44 | 0.040 |
Why?
| Genome, Viral | 1 | 2019 | 100 | 0.040 |
Why?
| Computational Biology | 1 | 2020 | 231 | 0.040 |
Why?
| DNA, Viral | 1 | 2019 | 142 | 0.040 |
Why?
| Fibrinogen | 1 | 2018 | 37 | 0.040 |
Why?
| Glycogen Synthase Kinase 3 | 1 | 2018 | 21 | 0.040 |
Why?
| Immunoglobulin A | 1 | 2018 | 54 | 0.040 |
Why?
| RNA, Messenger | 2 | 2016 | 1202 | 0.040 |
Why?
| Platelet Count | 2 | 2008 | 77 | 0.040 |
Why?
| Bone Marrow Cells | 2 | 2014 | 233 | 0.040 |
Why?
| Hospitalization | 1 | 2022 | 705 | 0.040 |
Why?
| Pathology, Molecular | 1 | 2018 | 24 | 0.040 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 52 | 0.040 |
Why?
| Oncogene Proteins, Fusion | 1 | 2018 | 60 | 0.040 |
Why?
| DNA-Binding Proteins | 1 | 2021 | 462 | 0.040 |
Why?
| Databases, Factual | 2 | 2013 | 684 | 0.040 |
Why?
| Immunoglobulin G | 1 | 2018 | 226 | 0.040 |
Why?
| Data Interpretation, Statistical | 2 | 2010 | 177 | 0.040 |
Why?
| Promoter Regions, Genetic | 1 | 2020 | 520 | 0.040 |
Why?
| Kidney Function Tests | 1 | 2017 | 59 | 0.040 |
Why?
| False Positive Reactions | 1 | 2017 | 68 | 0.040 |
Why?
| Child | 2 | 2020 | 7341 | 0.040 |
Why?
| Lamins | 1 | 2016 | 6 | 0.040 |
Why?
| Chromosomes, Human, Pair 16 | 1 | 2016 | 20 | 0.040 |
Why?
| Glomerular Filtration Rate | 1 | 2017 | 138 | 0.040 |
Why?
| Internationality | 1 | 2017 | 49 | 0.040 |
Why?
| Cell Transformation, Neoplastic | 1 | 2018 | 200 | 0.040 |
Why?
| Alkaline Phosphatase | 1 | 2017 | 99 | 0.040 |
Why?
| Genes, ras | 1 | 2016 | 48 | 0.040 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 74 | 0.040 |
Why?
| Genes, p53 | 1 | 2016 | 60 | 0.040 |
Why?
| Amino Acid Sequence | 1 | 2018 | 767 | 0.040 |
Why?
| Glycolysis | 1 | 2016 | 73 | 0.040 |
Why?
| Proteolysis | 1 | 2016 | 102 | 0.030 |
Why?
| Chromosome Mapping | 2 | 2006 | 175 | 0.030 |
Why?
| Enzyme Activation | 1 | 2016 | 329 | 0.030 |
Why?
| Prevalence | 1 | 2019 | 1025 | 0.030 |
Why?
| Image Interpretation, Computer-Assisted | 1 | 2016 | 119 | 0.030 |
Why?
| Phosphorylation | 1 | 2016 | 614 | 0.030 |
Why?
| Gene Fusion | 1 | 2014 | 14 | 0.030 |
Why?
| Asymptomatic Diseases | 1 | 2014 | 43 | 0.030 |
Why?
| Interspersed Repetitive Sequences | 1 | 2014 | 10 | 0.030 |
Why?
| Karyotype | 1 | 2014 | 19 | 0.030 |
Why?
| Capsid | 1 | 2014 | 3 | 0.030 |
Why?
| Lymphocyte Culture Test, Mixed | 1 | 2014 | 8 | 0.030 |
Why?
| Myocardium | 1 | 2017 | 441 | 0.030 |
Why?
| Kidney Diseases | 1 | 2017 | 293 | 0.030 |
Why?
| HIV-1 | 1 | 2014 | 72 | 0.030 |
Why?
| Homozygote | 1 | 2013 | 60 | 0.030 |
Why?
| Cerebrospinal Fluid | 1 | 2013 | 35 | 0.030 |
Why?
| Nicotinamide Mononucleotide | 1 | 2013 | 4 | 0.030 |
Why?
| Acrylamides | 1 | 2013 | 8 | 0.030 |
Why?
| Genetic Vectors | 1 | 2014 | 139 | 0.030 |
Why?
| Receptors, CXCR4 | 1 | 2013 | 31 | 0.030 |
Why?
| Chemokine CXCL12 | 1 | 2013 | 31 | 0.030 |
Why?
| NAD | 1 | 2013 | 46 | 0.030 |
Why?
| Niacinamide | 1 | 2013 | 25 | 0.030 |
Why?
| Dependovirus | 1 | 2014 | 102 | 0.030 |
Why?
| Enzyme Induction | 1 | 2013 | 80 | 0.030 |
Why?
| Sirtuin 1 | 1 | 2013 | 29 | 0.030 |
Why?
| Amides | 1 | 2013 | 43 | 0.030 |
Why?
| Diagnosis, Differential | 1 | 2017 | 1136 | 0.030 |
Why?
| Transplantation Chimera | 2 | 2003 | 15 | 0.030 |
Why?
| Gene Knockdown Techniques | 1 | 2013 | 125 | 0.030 |
Why?
| Nitriles | 1 | 2013 | 69 | 0.030 |
Why?
| RNA, Small Interfering | 1 | 2013 | 252 | 0.030 |
Why?
| Piperidines | 1 | 2013 | 103 | 0.030 |
Why?
| Induction Chemotherapy | 1 | 2012 | 59 | 0.030 |
Why?
| Lymphocyte Count | 1 | 2011 | 23 | 0.030 |
Why?
| Chemokine CXCL10 | 1 | 2011 | 20 | 0.030 |
Why?
| Acute Disease | 1 | 2013 | 403 | 0.030 |
Why?
| Infant | 1 | 2020 | 3817 | 0.030 |
Why?
| HIV Infections | 1 | 2016 | 394 | 0.030 |
Why?
| Antibodies, Neutralizing | 1 | 2011 | 75 | 0.030 |
Why?
| Tomography, X-Ray Computed | 1 | 2017 | 1213 | 0.020 |
Why?
| Pharmacogenetics | 1 | 2011 | 55 | 0.020 |
Why?
| Sex Factors | 1 | 2013 | 767 | 0.020 |
Why?
| Clinical Trials, Phase I as Topic | 1 | 2010 | 30 | 0.020 |
Why?
| Clinical Trials, Phase III as Topic | 1 | 2010 | 48 | 0.020 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2010 | 51 | 0.020 |
Why?
| Microarray Analysis | 1 | 2010 | 84 | 0.020 |
Why?
| International Classification of Diseases | 1 | 2010 | 65 | 0.020 |
Why?
| Argonaute Proteins | 1 | 2010 | 11 | 0.020 |
Why?
| Enzyme Inhibitors | 1 | 2013 | 446 | 0.020 |
Why?
| RNA-Binding Proteins | 1 | 2011 | 136 | 0.020 |
Why?
| Oligonucleotides | 1 | 2010 | 76 | 0.020 |
Why?
| Polyploidy | 1 | 2009 | 11 | 0.020 |
Why?
| Bone Marrow Examination | 1 | 2009 | 12 | 0.020 |
Why?
| L-Lactate Dehydrogenase | 1 | 2009 | 79 | 0.020 |
Why?
| Hematopoietic Stem Cells | 1 | 2011 | 215 | 0.020 |
Why?
| Ploidies | 1 | 2008 | 13 | 0.020 |
Why?
| Neoplasm Metastasis | 1 | 2009 | 252 | 0.020 |
Why?
| Chromosomes, Human, Pair 13 | 1 | 2008 | 41 | 0.020 |
Why?
| Serum Albumin | 1 | 2008 | 62 | 0.020 |
Why?
| Polyethylene Glycols | 1 | 2008 | 106 | 0.020 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2008 | 219 | 0.020 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2010 | 596 | 0.020 |
Why?
| Age Distribution | 1 | 2007 | 198 | 0.020 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2007 | 49 | 0.020 |
Why?
| Multigene Family | 1 | 2006 | 54 | 0.020 |
Why?
| Recombinant Proteins | 1 | 2008 | 569 | 0.020 |
Why?
| Cyclin D | 1 | 2006 | 20 | 0.020 |
Why?
| Syndecans | 1 | 2006 | 43 | 0.020 |
Why?
| RNA, Neoplasm | 1 | 2006 | 54 | 0.020 |
Why?
| Cyclins | 1 | 2006 | 54 | 0.020 |
Why?
| Proteoglycans | 1 | 2006 | 96 | 0.020 |
Why?
| Leukemia, Myeloid, Acute | 1 | 2007 | 191 | 0.020 |
Why?
| Brain | 1 | 2013 | 1387 | 0.020 |
Why?
| Survivors | 1 | 2006 | 137 | 0.020 |
Why?
| Pregnancy | 1 | 2011 | 2620 | 0.010 |
Why?
| Lymphocyte Transfusion | 1 | 2003 | 12 | 0.010 |
Why?
| Probability | 1 | 2003 | 176 | 0.010 |
Why?
| Administration, Oral | 1 | 2003 | 459 | 0.010 |
Why?
| Tissue Donors | 1 | 2003 | 110 | 0.010 |
Why?
|
|
Van Rhee's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|